Key Points
- Veeva SVP Jonathan Faddis sold 5,198 shares for approximately $1.56 million, reducing his direct ownership by 55.7%. The transaction was made under a pre-arranged Rule 10b5-1 plan.
- Veeva reported stronger-than-expected quarterly results, with adjusted EPS of $2.35 versus the $2.23 consensus and revenue of $927.96 million, up 17.6% year over year.
- Analyst sentiment remains favorable: 19 analysts rate the stock a Buy, eight rate it Hold, and one rates it Sell, producing a consensus “Moderate Buy” rating and an average price target of $285.92.
Veeva Systems Inc. (NYSE:VEEV - Get Free Report) SVP Jonathan Faddis sold 5,198 shares of the business's stock in a transaction dated Wednesday, October 14th. The stock was sold at an average price of $299.72, for a total transaction of $1,557,944.56. Following the completion of the transaction, the senior vice president owned 4,130 shares of the company's stock, valued at $1,237,843.60. This represents a 55.72% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Veeva Systems Stock Performance
VEEV stock traded down $2.13 on Friday, hitting $310.90. 1,730,063 shares of the company's stock were exchanged, compared to its average volume of 1,686,745. The firm has a 50 day moving average price of $269.81 and a two-hundred day moving average price of $207.95. Veeva Systems Inc. has a 12-month low of $148.05 and a 12-month high of $319.95. The stock has a market cap of $50.34 billion, a P/E ratio of 51.14, a price-to-earnings-growth ratio of 1.34 and a beta of 0.93.
Veeva Systems (NYSE:VEEV - Get Free Report) last issued its earnings results on Wednesday, August 26th. The technology company reported $2.35 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.23 by $0.12. The company had revenue of $927.96 million during the quarter, compared to analyst estimates of $905.38 million. Veeva Systems had a return on equity of 14.25% and a net margin of 29.34%. The firm's quarterly revenue was up 17.6% on a year-over-year basis. During the same quarter last year, the business posted $1.99 EPS. Veeva Systems has set its FY 2027 guidance at 9.210-9.210 EPS and its Q3 2027 guidance at 2.330-2.340 EPS. Sell-side analysts expect that Veeva Systems Inc. will post 6.70 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
VEEV has been the subject of several research analyst reports. Canaccord Genuity Group upped their target price on Veeva Systems from $220.00 to $260.00 and gave the stock a "hold" rating in a research note on Thursday, August 27th. Piper Sandler boosted their price target on shares of Veeva Systems from $295.00 to $320.00 and gave the stock an "overweight" rating in a report on Thursday, August 27th. UBS Group boosted their price target on shares of Veeva Systems from $190.00 to $290.00 and gave the stock a "neutral" rating in a report on Thursday, August 27th. Wells Fargo & Company restated an "overweight" rating and set a $330.00 price objective on shares of Veeva Systems in a research report on Tuesday, September 8th. Finally, Jefferies Financial Group reaffirmed a "buy" rating and set a $295.00 price objective on shares of Veeva Systems in a report on Thursday, August 27th. Nineteen equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Veeva Systems presently has a consensus rating of "Moderate Buy" and an average target price of $285.92.
Read Our Latest Stock Analysis on VEEV
Veeva Systems News Roundup
Here are the key news stories impacting Veeva Systems this week:
- Positive Sentiment: IQVIA selected Veeva’s clinical software as an enterprise standard. IQVIA will use Veeva Clinical Trial Management System, eTMF, Study Startup, and Site Connect across its global research operations. The agreement expands Veeva’s role in IQVIA’s clinical workflow, strengthens its position with contract research organizations and biopharma customers, and could support recurring revenue growth. Veeva Systems Becomes Default Clinical Software Across a Major Research Partner
- Positive Sentiment: Technical momentum and institutional interest have accelerated. Reports said Veeva broke above a buy point as “big money” added exposure to the company’s AI-related software opportunity. Shares subsequently reached a fresh 52-week high and posted sizable single-session gains, attracting additional momentum-oriented investors. Veeva Stock Breaks Out As Big Money Grabs Exposure To The AI Software Play
- Positive Sentiment: Analyst coverage remains favorable. Oppenheimer maintained a $325 price target, while the average Wall Street recommendation remains positive. These views reinforce the market’s expectation that Veeva can continue expanding despite a potential moderation in research-and-development growth. Oppenheimer Keeps $325 Target for Veeva Systems Stock
- Neutral Sentiment: More than 175 emerging biotechs are reportedly using Veeva Basics, indicating continued adoption of the company’s broader cloud software platform. However, the immediate financial impact was not quantified. Veeva’s Clinical Technology Moat and IQVIA Deal
- Negative Sentiment: Senior Vice President Jonathan Faddis sold 5,198 shares for approximately $1.56 million, reducing his direct ownership by 55.7%. The transaction occurred under a pre-arranged Rule 10b5-1 plan, which limits its significance as a discretionary bearish signal, but insider selling can still temper enthusiasm after a strong rally. SEC Insider Transaction Filing
Institutional Trading of Veeva Systems
Several hedge funds have recently made changes to their positions in the company. Czech National Bank purchased a new stake in Veeva Systems during the 2nd quarter worth approximately $7,584,000. Vulcan Value Partners LLC purchased a new position in Veeva Systems in the 2nd quarter valued at approximately $3,769,000. East Coast Asset Management LLC. acquired a new position in shares of Veeva Systems in the first quarter worth $1,665,000. Rockland Trust Co. increased its position in shares of Veeva Systems by 21.4% during the second quarter. Rockland Trust Co. now owns 173,760 shares of the technology company's stock worth $30,837,000 after acquiring an additional 30,678 shares during the period. Finally, Westwind Capital purchased a new stake in shares of Veeva Systems during the third quarter worth $1,684,000. Hedge funds and other institutional investors own 88.20% of the company's stock.
Veeva Systems Company Profile
(
Get Free Report)
Veeva Systems Inc is a cloud software company that provides applications and services for the life sciences industry. Its customers include pharmaceutical, biotechnology, medical device and other organizations involved in developing, manufacturing and commercializing regulated products.
The company's product portfolio includes the Veeva Vault platform, which supports areas such as clinical operations, regulatory affairs, quality management, safety and medical communications. Veeva also offers commercial and customer relationship management applications, data and analytics products, and services designed to help life sciences companies manage relationships with healthcare professionals, oversee content and improve operational efficiency.
Founded in 2007, Veeva serves customers globally and has expanded its offerings from commercial software into research, development, manufacturing and quality processes.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
